Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular's investigational product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD). BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular T ...